Targeting AKT for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The AKT/PKB pathway is vital for cancer cell survival, proliferation, and angiogenesis.
• Aberrant AKT signaling, driven by PI3K or other factors, is implicated in various cancers.
• AKT represents a validated therapeutic target for anticancer drug development.

Purpose of the Study:

• To review the biological role of AKT in cancer.
• To summarize different classes of AKT inhibitors.
• To explore the efficacy of AKT inhibitors in monotherapy and combination treatments.

Main Methods:

• Literature review of AKT's biological function.
• Analysis of AKT inhibitor classes and their mechanisms.
• Evaluation of preclinical and clinical data on AKT inhibitor efficacy.

Main Results:

• AKT inhibitors target a key pathway in cancer cell growth and survival.
• Efficacy of AKT inhibitors is explored as monotherapies and in combination regimens.
• Complex resistance mechanisms necessitate combination strategies for improved response.

Conclusions:

• AKT inhibitors are promising anticancer agents, but resistance is a challenge.
• Combination therapies are crucial to enhance clinical response and overcome resistance.
• Biomarker identification is essential for effective AKT inhibitor-based cancer treatment.